Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Date:3/3/2010

trategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the SEC. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly reports for the first, second and third quarters of 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 2013 was a banner ... Brain State Technologies®. They saw continued independent research ... Medical Center who were awarded a $1 million ... research papers published in “Brain and Behavior” a ... in First for Women Magazine and they were ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal ... January 23, 2014 at 2pm EST (11am PST), ... Knowledge.” The topic focuses on how technology can ... drive mission critical decisions for government agencies. The ... Synopsis: Big Data has become an obstacle for ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ... (known by its acronym GA, based on ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ... safety, clinical outcomes, and medication adherence. , It ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
(Date:4/15/2014)... researchers have previously shown that a genetic pre-disposition to ... a new study, Frank Booth, a professor in the ... link between the genetic pre-disposition for high levels of ... occurs. , For his study, Booth selectively bred rats ... laziness. Booth then put the rats in cages with ...
(Date:4/15/2014)... Western Reserve University dental researchers have found a ... cells from the mouth to study how the ... , By isolating some specialized immune cells (white ... they fight diseases in the mouthor reject foreign ... to learn more about treating and preventing such ...
(Date:4/15/2014)... There are many viral diseases in the world for ... dengue fever, which is spread by mosquitoes in the ... is more familiar in Finland and is easily spread ... small children and the elderly. , Researchers at Aalto ... succeeded in preliminary tests to prevent the spread of ...
Breaking Biology News(10 mins):Genetic pre-disposition toward exercise and mental development may be linked 2New method isolates immune cells for researchers to study how they ward off oral diseases 2Nanocrystalline cellulose modified into an efficient viral inhibitor 2
... University of California, San Diego School of Medicine say that ... molecule boosted disease protection in early hominids, and may have ... Homo . The findings, published in this week,s early ... of Sciences , are among the first evidence of a ...
... Research by biologists at the University of York and ... about the way the brain is affected by age. ... Medicine and Dentistry in Plymouth, they have studied responses ... The researchers discovered that under stressful conditions, such as ...
... off to Antarctica for the first stage of an ambitious ... lake buried beneath three kilometres of solid ice. This extraordinary ... knowledge about the evolution of life on Earth and other ... climate. Transporting nearly 70 tonnes of equipment the ,advance ...
Cached Biology News:Sexual selection by sugar molecule helped determine human origins 2Sexual selection by sugar molecule helped determine human origins 3Researchers study aging's effect on the brain 2Engineering team heads to Antarctica to explore hidden lake 2Engineering team heads to Antarctica to explore hidden lake 3
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
... Goat anti-Human Alpha 1 Acid ... azide Goats were immunized ... glycoprotein in Freund's adjuvant. ... absorbed to ensure specificity. ...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Request Info...
Biology Products: